<SEC-DOCUMENT>0001737287-21-000021.txt : 20210505
<SEC-HEADER>0001737287-21-000021.hdr.sgml : 20210505
<ACCEPTANCE-DATETIME>20210505162041
ACCESSION NUMBER:		0001737287-21-000021
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		16
CONFORMED PERIOD OF REPORT:	20210505
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20210505
DATE AS OF CHANGE:		20210505

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Allogene Therapeutics, Inc.
		CENTRAL INDEX KEY:			0001737287
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				823562771
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38693
		FILM NUMBER:		21893636

	BUSINESS ADDRESS:	
		STREET 1:		210 EAST GRAND AVENUE
		CITY:			SOUTH SAN FRANCISCO
		STATE:			CA
		ZIP:			94080
		BUSINESS PHONE:		(650) 457-2700

	MAIL ADDRESS:	
		STREET 1:		210 EAST GRAND AVENUE
		CITY:			SOUTH SAN FRANCISCO
		STATE:			CA
		ZIP:			94080
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>allo-20210505.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2021 Workiva--><!--r:093e9ea0-7f33-48b7-ab74-020f9c8ee32d,g:99b413ce-972b-4416-8868-b52d8e8c6c1a,d:89c9238a8f404588869562de819252aa--><html xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns="http://www.w3.org/1999/xhtml" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>allo-20210505</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="i259d1a27ddae4f849a0c7f0668bff90e_D20210505-20210505" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOjg5YzkyMzhhOGY0MDQ1ODg4Njk1NjJkZTgxOTI1MmFhL3NlYzo4OWM5MjM4YThmNDA0NTg4ODY5NTYyZGU4MTkyNTJhYV80L2ZyYWc6OWExNTI0NWJiMjUzNDJhYWE1YzkyZDZiYmMzZjc3N2QvdGFibGU6MGEzMzhiZTc0YWRjNGI2MTgzOWZjM2E4MzQ4NDRiMWEvdGFibGVyYW5nZTowYTMzOGJlNzRhZGM0YjYxODM5ZmMzYTgzNDg0NGIxYV8xLTEtMS0xLTA_378bb10a-7a03-4490-a120-a321b1cd39c4">0001737287</ix:nonNumeric><ix:nonNumeric contextRef="i259d1a27ddae4f849a0c7f0668bff90e_D20210505-20210505" format="ixt:booleanfalse" name="dei:AmendmentFlag" id="id3VybDovL2RvY3MudjEvZG9jOjg5YzkyMzhhOGY0MDQ1ODg4Njk1NjJkZTgxOTI1MmFhL3NlYzo4OWM5MjM4YThmNDA0NTg4ODY5NTYyZGU4MTkyNTJhYV80L2ZyYWc6OWExNTI0NWJiMjUzNDJhYWE1YzkyZDZiYmMzZjc3N2QvdGFibGU6MGEzMzhiZTc0YWRjNGI2MTgzOWZjM2E4MzQ4NDRiMWEvdGFibGVyYW5nZTowYTMzOGJlNzRhZGM0YjYxODM5ZmMzYTgzNDg0NGIxYV8yLTEtMS0xLTA_19cd2edf-d3dc-4f94-b1ff-821e9d2bc469">FALSE</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="allo-20210505.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="i259d1a27ddae4f849a0c7f0668bff90e_D20210505-20210505"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-05-05</xbrli:startDate><xbrli:endDate>2021-05-05</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="i89c9238a8f404588869562de819252aa_1"></div><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:4pt"><span><br/></span></div><div style="margin-bottom:6pt;margin-top:4pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="margin-top:4pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Washington, D.C. 20549</span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">____________________</span></div><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="i259d1a27ddae4f849a0c7f0668bff90e_D20210505-20210505" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOjg5YzkyMzhhOGY0MDQ1ODg4Njk1NjJkZTgxOTI1MmFhL3NlYzo4OWM5MjM4YThmNDA0NTg4ODY5NTYyZGU4MTkyNTJhYV8xL2ZyYWc6ZjFiOGEyYTFmZjJlNGQzMWE3M2M1MzVlOWEzNDhhYzUvdGV4dHJlZ2lvbjpmMWI4YTJhMWZmMmU0ZDMxYTczYzUzNWU5YTM0OGFjNV8xNTE1_5328b475-39b2-432c-b53e-1f18c2a70f27">8-K</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">____________________</span></div><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">CURRENT REPORT</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Pursuant to Section&#160;13 or 15(d)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">of the Securities Exchange Act of 1934</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Date of Report (Date of earliest event reported): <ix:nonNumeric contextRef="i259d1a27ddae4f849a0c7f0668bff90e_D20210505-20210505" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate" id="id3VybDovL2RvY3MudjEvZG9jOjg5YzkyMzhhOGY0MDQ1ODg4Njk1NjJkZTgxOTI1MmFhL3NlYzo4OWM5MjM4YThmNDA0NTg4ODY5NTYyZGU4MTkyNTJhYV8xL2ZyYWc6ZjFiOGEyYTFmZjJlNGQzMWE3M2M1MzVlOWEzNDhhYzUvdGV4dHJlZ2lvbjpmMWI4YTJhMWZmMmU0ZDMxYTczYzUzNWU5YTM0OGFjNV8yNjc_e950d86f-539a-47f7-95d3-a15224e12c9e">May 5, 2021</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">_______________________</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:22pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i259d1a27ddae4f849a0c7f0668bff90e_D20210505-20210505" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOjg5YzkyMzhhOGY0MDQ1ODg4Njk1NjJkZTgxOTI1MmFhL3NlYzo4OWM5MjM4YThmNDA0NTg4ODY5NTYyZGU4MTkyNTJhYV8xL2ZyYWc6ZjFiOGEyYTFmZjJlNGQzMWE3M2M1MzVlOWEzNDhhYzUvdGV4dHJlZ2lvbjpmMWI4YTJhMWZmMmU0ZDMxYTczYzUzNWU5YTM0OGFjNV8xNTEx_1cd1ea4e-f532-4380-88fd-10cabf85ad08">Allogene Therapeutics, Inc.</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Exact name of registrant as specified in its charter)</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">____________________________</span></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:32.135%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.282%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.283%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i259d1a27ddae4f849a0c7f0668bff90e_D20210505-20210505" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode" id="id3VybDovL2RvY3MudjEvZG9jOjg5YzkyMzhhOGY0MDQ1ODg4Njk1NjJkZTgxOTI1MmFhL3NlYzo4OWM5MjM4YThmNDA0NTg4ODY5NTYyZGU4MTkyNTJhYV8xL2ZyYWc6ZjFiOGEyYTFmZjJlNGQzMWE3M2M1MzVlOWEzNDhhYzUvdGFibGU6YTM3ZWJlZTA0ZDdlNDNiNjg2YzYxMzE3Y2QxZmViZTgvdGFibGVyYW5nZTphMzdlYmVlMDRkN2U0M2I2ODZjNjEzMTdjZDFmZWJlOF8wLTAtMS0xLTA_7536e7ef-fbd7-49f8-a9e4-286b62fd5a3d">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i259d1a27ddae4f849a0c7f0668bff90e_D20210505-20210505" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOjg5YzkyMzhhOGY0MDQ1ODg4Njk1NjJkZTgxOTI1MmFhL3NlYzo4OWM5MjM4YThmNDA0NTg4ODY5NTYyZGU4MTkyNTJhYV8xL2ZyYWc6ZjFiOGEyYTFmZjJlNGQzMWE3M2M1MzVlOWEzNDhhYzUvdGFibGU6YTM3ZWJlZTA0ZDdlNDNiNjg2YzYxMzE3Y2QxZmViZTgvdGFibGVyYW5nZTphMzdlYmVlMDRkN2U0M2I2ODZjNjEzMTdjZDFmZWJlOF8wLTEtMS0xLTA_b9f9797f-d0c2-4eab-a1c9-736e2700d963">001-38693</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i259d1a27ddae4f849a0c7f0668bff90e_D20210505-20210505" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOjg5YzkyMzhhOGY0MDQ1ODg4Njk1NjJkZTgxOTI1MmFhL3NlYzo4OWM5MjM4YThmNDA0NTg4ODY5NTYyZGU4MTkyNTJhYV8xL2ZyYWc6ZjFiOGEyYTFmZjJlNGQzMWE3M2M1MzVlOWEzNDhhYzUvdGFibGU6YTM3ZWJlZTA0ZDdlNDNiNjg2YzYxMzE3Y2QxZmViZTgvdGFibGVyYW5nZTphMzdlYmVlMDRkN2U0M2I2ODZjNjEzMTdjZDFmZWJlOF8wLTItMS0xLTA_59c319cf-700b-445a-933f-e3599174b4f4">82-3562771</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(State or other jurisdiction</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">of incorporation)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Commission</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">File Number)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(I.R.S. Employer</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Identification No.)</span></div></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i259d1a27ddae4f849a0c7f0668bff90e_D20210505-20210505" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOjg5YzkyMzhhOGY0MDQ1ODg4Njk1NjJkZTgxOTI1MmFhL3NlYzo4OWM5MjM4YThmNDA0NTg4ODY5NTYyZGU4MTkyNTJhYV8xL2ZyYWc6ZjFiOGEyYTFmZjJlNGQzMWE3M2M1MzVlOWEzNDhhYzUvdGV4dHJlZ2lvbjpmMWI4YTJhMWZmMmU0ZDMxYTczYzUzNWU5YTM0OGFjNV8xNTEz_6826b6cb-cea7-432e-9f81-89f70e5d2d37">210 East Grand Avenue</ix:nonNumeric>, <ix:nonNumeric contextRef="i259d1a27ddae4f849a0c7f0668bff90e_D20210505-20210505" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOjg5YzkyMzhhOGY0MDQ1ODg4Njk1NjJkZTgxOTI1MmFhL3NlYzo4OWM5MjM4YThmNDA0NTg4ODY5NTYyZGU4MTkyNTJhYV8xL2ZyYWc6ZjFiOGEyYTFmZjJlNGQzMWE3M2M1MzVlOWEzNDhhYzUvdGV4dHJlZ2lvbjpmMWI4YTJhMWZmMmU0ZDMxYTczYzUzNWU5YTM0OGFjNV8xNTA4_aea7ba84-7d4e-45e2-84ee-4db58d38be79">South San Francisco</ix:nonNumeric>, <ix:nonNumeric contextRef="i259d1a27ddae4f849a0c7f0668bff90e_D20210505-20210505" format="ixt-sec:stateprovnameen" name="dei:EntityAddressStateOrProvince" id="id3VybDovL2RvY3MudjEvZG9jOjg5YzkyMzhhOGY0MDQ1ODg4Njk1NjJkZTgxOTI1MmFhL3NlYzo4OWM5MjM4YThmNDA0NTg4ODY5NTYyZGU4MTkyNTJhYV8xL2ZyYWc6ZjFiOGEyYTFmZjJlNGQzMWE3M2M1MzVlOWEzNDhhYzUvdGV4dHJlZ2lvbjpmMWI4YTJhMWZmMmU0ZDMxYTczYzUzNWU5YTM0OGFjNV8xNTA5_c63d48bc-761f-46ab-993a-76a59f454133">California</ix:nonNumeric> <ix:nonNumeric contextRef="i259d1a27ddae4f849a0c7f0668bff90e_D20210505-20210505" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOjg5YzkyMzhhOGY0MDQ1ODg4Njk1NjJkZTgxOTI1MmFhL3NlYzo4OWM5MjM4YThmNDA0NTg4ODY5NTYyZGU4MTkyNTJhYV8xL2ZyYWc6ZjFiOGEyYTFmZjJlNGQzMWE3M2M1MzVlOWEzNDhhYzUvdGV4dHJlZ2lvbjpmMWI4YTJhMWZmMmU0ZDMxYTczYzUzNWU5YTM0OGFjNV8xNTE2_24c0c699-d1b1-4169-be10-a8f7217ce45b">94080</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(Address of principal executive offices including zip code)</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Registrant&#8217;s telephone number, including area code: (<ix:nonNumeric contextRef="i259d1a27ddae4f849a0c7f0668bff90e_D20210505-20210505" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOjg5YzkyMzhhOGY0MDQ1ODg4Njk1NjJkZTgxOTI1MmFhL3NlYzo4OWM5MjM4YThmNDA0NTg4ODY5NTYyZGU4MTkyNTJhYV8xL2ZyYWc6ZjFiOGEyYTFmZjJlNGQzMWE3M2M1MzVlOWEzNDhhYzUvdGV4dHJlZ2lvbjpmMWI4YTJhMWZmMmU0ZDMxYTczYzUzNWU5YTM0OGFjNV8xNTE3_e1271258-0602-499f-9864-39081b86b20f">650</ix:nonNumeric>) <ix:nonNumeric contextRef="i259d1a27ddae4f849a0c7f0668bff90e_D20210505-20210505" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOjg5YzkyMzhhOGY0MDQ1ODg4Njk1NjJkZTgxOTI1MmFhL3NlYzo4OWM5MjM4YThmNDA0NTg4ODY5NTYyZGU4MTkyNTJhYV8xL2ZyYWc6ZjFiOGEyYTFmZjJlNGQzMWE3M2M1MzVlOWEzNDhhYzUvdGV4dHJlZ2lvbjpmMWI4YTJhMWZmMmU0ZDMxYTczYzUzNWU5YTM0OGFjNV8xNTE0_a5013c48-8bcc-48f6-8fc4-88d931bb1636">457-2700</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Former name or former address, if changed since last report.)</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">________________________________</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. of Form 8-K):</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:3.738%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.732%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:91.130%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i259d1a27ddae4f849a0c7f0668bff90e_D20210505-20210505" format="ixt-sec:boolballotbox" name="dei:WrittenCommunications" id="id3VybDovL2RvY3MudjEvZG9jOjg5YzkyMzhhOGY0MDQ1ODg4Njk1NjJkZTgxOTI1MmFhL3NlYzo4OWM5MjM4YThmNDA0NTg4ODY5NTYyZGU4MTkyNTJhYV8xL2ZyYWc6ZjFiOGEyYTFmZjJlNGQzMWE3M2M1MzVlOWEzNDhhYzUvdGFibGU6MWMyZWM3Y2ZhMGM1NGY0MDk4YWE2MmY5ZTIzODBmNzMvdGFibGVyYW5nZToxYzJlYzdjZmEwYzU0ZjQwOThhYTYyZjllMjM4MGY3M18wLTEtMS0xLTA_da72a612-3037-4d04-a715-c1cbef7cb4c4">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i259d1a27ddae4f849a0c7f0668bff90e_D20210505-20210505" format="ixt-sec:boolballotbox" name="dei:SolicitingMaterial" id="id3VybDovL2RvY3MudjEvZG9jOjg5YzkyMzhhOGY0MDQ1ODg4Njk1NjJkZTgxOTI1MmFhL3NlYzo4OWM5MjM4YThmNDA0NTg4ODY5NTYyZGU4MTkyNTJhYV8xL2ZyYWc6ZjFiOGEyYTFmZjJlNGQzMWE3M2M1MzVlOWEzNDhhYzUvdGFibGU6MWMyZWM3Y2ZhMGM1NGY0MDk4YWE2MmY5ZTIzODBmNzMvdGFibGVyYW5nZToxYzJlYzdjZmEwYzU0ZjQwOThhYTYyZjllMjM4MGY3M18xLTEtMS0xLTA_475e0b72-3d94-4039-b2b1-31496f29e3d6">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i259d1a27ddae4f849a0c7f0668bff90e_D20210505-20210505" format="ixt-sec:boolballotbox" name="dei:PreCommencementTenderOffer" id="id3VybDovL2RvY3MudjEvZG9jOjg5YzkyMzhhOGY0MDQ1ODg4Njk1NjJkZTgxOTI1MmFhL3NlYzo4OWM5MjM4YThmNDA0NTg4ODY5NTYyZGU4MTkyNTJhYV8xL2ZyYWc6ZjFiOGEyYTFmZjJlNGQzMWE3M2M1MzVlOWEzNDhhYzUvdGFibGU6MWMyZWM3Y2ZhMGM1NGY0MDk4YWE2MmY5ZTIzODBmNzMvdGFibGVyYW5nZToxYzJlYzdjZmEwYzU0ZjQwOThhYTYyZjllMjM4MGY3M18yLTEtMS0xLTA_b8618381-265d-44c7-8f18-254eaa26baf3">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i259d1a27ddae4f849a0c7f0668bff90e_D20210505-20210505" format="ixt-sec:boolballotbox" name="dei:PreCommencementIssuerTenderOffer" id="id3VybDovL2RvY3MudjEvZG9jOjg5YzkyMzhhOGY0MDQ1ODg4Njk1NjJkZTgxOTI1MmFhL3NlYzo4OWM5MjM4YThmNDA0NTg4ODY5NTYyZGU4MTkyNTJhYV8xL2ZyYWc6ZjFiOGEyYTFmZjJlNGQzMWE3M2M1MzVlOWEzNDhhYzUvdGFibGU6MWMyZWM3Y2ZhMGM1NGY0MDk4YWE2MmY5ZTIzODBmNzMvdGFibGVyYW5nZToxYzJlYzdjZmEwYzU0ZjQwOThhYTYyZjllMjM4MGY3M18zLTEtMS0xLTA_cc59cfe3-041f-4825-971f-52a16a5828c4">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</span></td></tr></table></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Securities registered pursuant to Section&#160;12(b) of the Act:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:31.744%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.744%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.746%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Title of each class</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Trading</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Symbol(s)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Name&#160;of&#160;each&#160;exchange</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">on&#160;which&#160;registered</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i259d1a27ddae4f849a0c7f0668bff90e_D20210505-20210505" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjg5YzkyMzhhOGY0MDQ1ODg4Njk1NjJkZTgxOTI1MmFhL3NlYzo4OWM5MjM4YThmNDA0NTg4ODY5NTYyZGU4MTkyNTJhYV8xL2ZyYWc6ZjFiOGEyYTFmZjJlNGQzMWE3M2M1MzVlOWEzNDhhYzUvdGFibGU6NGMzMTk1MGYxNWZhNGFjNjgzYzQyY2FlMzA2MmMzMjUvdGFibGVyYW5nZTo0YzMxOTUwZjE1ZmE0YWM2ODNjNDJjYWUzMDYyYzMyNV8xLTAtMS0xLTA_09d3d340-274b-4001-a50f-105ffc52bfb2">Common&#160;Stock,&#160;$0.001&#160;par&#160;value&#160;per&#160;share</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i259d1a27ddae4f849a0c7f0668bff90e_D20210505-20210505" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjg5YzkyMzhhOGY0MDQ1ODg4Njk1NjJkZTgxOTI1MmFhL3NlYzo4OWM5MjM4YThmNDA0NTg4ODY5NTYyZGU4MTkyNTJhYV8xL2ZyYWc6ZjFiOGEyYTFmZjJlNGQzMWE3M2M1MzVlOWEzNDhhYzUvdGFibGU6NGMzMTk1MGYxNWZhNGFjNjgzYzQyY2FlMzA2MmMzMjUvdGFibGVyYW5nZTo0YzMxOTUwZjE1ZmE0YWM2ODNjNDJjYWUzMDYyYzMyNV8xLTItMS0xLTA_b4272878-3c82-4e58-be0d-735ff9fa0f11">ALLO</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i259d1a27ddae4f849a0c7f0668bff90e_D20210505-20210505" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName" id="id3VybDovL2RvY3MudjEvZG9jOjg5YzkyMzhhOGY0MDQ1ODg4Njk1NjJkZTgxOTI1MmFhL3NlYzo4OWM5MjM4YThmNDA0NTg4ODY5NTYyZGU4MTkyNTJhYV8xL2ZyYWc6ZjFiOGEyYTFmZjJlNGQzMWE3M2M1MzVlOWEzNDhhYzUvdGFibGU6NGMzMTk1MGYxNWZhNGFjNjgzYzQyY2FlMzA2MmMzMjUvdGFibGVyYW5nZTo0YzMxOTUwZjE1ZmE0YWM2ODNjNDJjYWUzMDYyYzMyNV8xLTQtMS0xLTA_40a1c2e4-b69e-4546-98f3-f20dcb63c74b">The Nasdaq Stock Market LLC</ix:nonNumeric></span></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (&#167;&#160;230.405 of this chapter) or Rule 12b&#8211;2 of the Securities Exchange Act of 1934 (&#167;&#160;240.12b&#8211;2 of this chapter).</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Emerging growth company </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i259d1a27ddae4f849a0c7f0668bff90e_D20210505-20210505" format="ixt-sec:boolballotbox" name="dei:EntityEmergingGrowthCompany" id="id3VybDovL2RvY3MudjEvZG9jOjg5YzkyMzhhOGY0MDQ1ODg4Njk1NjJkZTgxOTI1MmFhL3NlYzo4OWM5MjM4YThmNDA0NTg4ODY5NTYyZGU4MTkyNTJhYV8xL2ZyYWc6ZjFiOGEyYTFmZjJlNGQzMWE3M2M1MzVlOWEzNDhhYzUvdGV4dHJlZ2lvbjpmMWI4YTJhMWZmMmU0ZDMxYTczYzUzNWU5YTM0OGFjNV8xNTEw_b9403d1f-7507-4b4f-bfad-c5f84c5084c4">&#9744;</ix:nonNumeric></span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&#160;13(a) of the Exchange Act.&#160;&#160;&#9744;</span></div><div style="margin-top:9pt"><span><br/></span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div></div></div><div id="i89c9238a8f404588869562de819252aa_7"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;2.02&#160;&#160;&#160;&#160;Results of Operations and Financial Condition.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May&#160;5, 2021, Allogene Therapeutics, Inc. (the &#8220;Company&#8221;) provided a corporate update and announced its financial results for the quarter ended March&#160;31, 2021 in the press release attached hereto as Exhibit&#160;99.1, which is incorporated herein by reference.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information in this Item&#160;2.02, including the attached Exhibit 99.1, is being furnished and shall not be deemed &#8220;filed&#8221; for the purposes of Section&#160;18 of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), or otherwise subject to the liabilities of that Section, nor shall it be deemed incorporated by reference in any filing made by the Company under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.</span></div><div><span><br/></span></div><div id="i89c9238a8f404588869562de819252aa_10"></div><div style="-sec-extract:summary;margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;9.01&#160;&#160;&#160;&#160;Financial Statements and Exhibits.</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:12.976%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:84.091%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(d)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Description</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="allo-20210331xexx991q121.htm">Press Release of the Company, dated May 5, 202</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="allo-20210331xexx991q121.htm">1</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="allo-20210331xexx991q121.htm">.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The cover page of this report has been formatted in Inline XBRL.</span></td></tr></table></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div></div></div><div id="i89c9238a8f404588869562de819252aa_13"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:57.025%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.999%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:28.621%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.955%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">ALLOGENE THERAPEUTICS, INC.</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ David Chang, M.D., Ph.D.</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">David Chang, M.D., Ph.D.</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">President, Chief Executive Officer</span></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Dated: May 5, 2021</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>allo-20210331xexx991q121.htm
<DESCRIPTION>EX-99.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="iecbbf3d2c20a41eab9b6439a89ecb2eb_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div><div><font><br></font></div></div><div style="margin-bottom:10pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 99.1</font></div><div style="margin-top:10pt"><img alt="g725933allogenea061.jpg" src="g725933allogenea061.jpg" style="height:41px;margin-bottom:5pt;vertical-align:text-bottom;width:176px"></div><div style="padding-left:4.5pt;padding-right:4.5pt;text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Allogene Therapeutics Reports First Quarter 2021 Financial Results </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"> </font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">CD19 Program Highlights</font></div><div style="padding-left:58.5pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">Data from the ALLO-501 ALPHA Study and ALLO-501A ALPHA2 Study to be Presented at the American Society of Clinical Oncology (ASCO) Annual Meeting</font></div><div style="padding-left:58.5pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt"> Longer Term Follow-Up from the ALPHA Study and Consolidation Dosing in Both ALPHA and ALPHA2 Study to be Included</font></div><div style="padding-left:58.5pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">Allogene to Host Virtual CD19 Forum to Review ASCO Datasets on May 19, 2021 at 2&#58;30 p.m. PT&#47;5&#58;30 p.m. ET</font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">BCMA Program Highlights</font></div><div style="padding-left:58.5pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">FDA Granted RMAT Designation to ALLO-715, the First for an AlloCAR TTM Candidate for Relapsed&#47;Refractory Multiple Myeloma</font></div><div style="padding-left:58.5pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">Initiated Combination Arm of the UNIVERSAL Trial with ALLO-715 and Nirogacestat </font></div><div style="padding-left:58.5pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">FDA Cleared IND Application for ALLO-605, the First TurboCAR&#8482; T Cell Candidate Targeting BCMA for Patients with Relapsed&#47;Refractory Multiple Myeloma</font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Solid Tumor Program Highlights</font></div><div style="padding-left:58.5pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">TRAVERSE Trial Initiated for ALLO-316 (anti-CD70) in Patients with Advanced or Metastatic Renal Cell Carcinoma </font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">Ended First Quarter with $964 Million in Cash, Cash Equivalents and Investments</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">Quarterly Conference Call and Webcast Scheduled for 2&#58;00 PM PT&#47;5&#58;00 PM ET</font></div><div style="padding-left:4.5pt;padding-right:4.5pt;text-align:center"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">SOUTH SAN FRANCISCO, Calif., May 5, 2021 -- Allogene Therapeutics, Inc. (Nasdaq&#58; ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T&#8482;) therapies for cancer, today provided a corporate update and reported financial results for the quarter ended March 31, 2021.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#34;We&#8217;ve had a strong start to the year as evidenced by the significant clinical and regulatory progress made across our growing AlloCAR T portfolio, including the start of our first solid tumors study,&#8221; said David Chang, M.D., Ph.D., President, Chief Executive Officer and Co-Founder of Allogene. &#8220;We believe our progress demonstrates our ability to advance the field of allogeneic CAR T cell therapy and we look forward to sharing data from our CD19 program on May 19th during our virtual forum event.&#8221;</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Pipeline Highlights</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Anti-CD19 Program</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">Updated data from the dose escalation Phase 1 ALPHA study of ALLO-501 in relapsed&#47;refractory non-Hodgkin lymphoma (NHL) will be jointly presented with initial data from the ALPHA2 study of ALLO-501A at the American Society of Clinical Oncology (ASCO) annual meeting. The presentation will include longer-term follow-up from the initial cohort of patients reported at ASCO 2020, additional data on patients treated  subsequent to ASCO 2020, dose escalation data from ALPHA2, and initial results from patients treated with consolidation dosing of ALLO-501 and ALLO-501A. A separate poster presentation will detail safety and biomarker findings from ALLO-647, Allogene&#8217;s wholly owned antibody used for lymphodepletion with fludarabine (Flu)&#47;cyclophosphamide (Cy) in patients with relapsed&#47;refractory NHL and multiple myeloma.</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Subject to further study progress and data, the Company plans to initiate a potentially pivotal Phase 2 trial of ALLO-501A by the end of 2021.</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">On May 19, 2021, the Company will host a virtual CD19 Forum focused on clinical data being presented at ASCO, along with the Company&#8217;s vision for the future of CAR T therapy. In addition to presentations from Company management, the Forum will include a discussion with clinical investigators.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Anti-BCMA Program</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company continues to execute on its portfolio of anti-B cell maturation antigen (BCMA) therapies in patients with multiple myeloma (MM).</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">ALLO-715 UNIVERSAL Trial</font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div><div><font><br></font></div></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#9702;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">The U.S. Food and Drug Administration (FDA) granted Regenerative Medicine Advanced Therapy (RMAT) designation to ALLO-715, Allogene&#8217;s most advanced AlloCAR T candidate for relapsed&#47;refractory MM. The designation follows proof-of-concept data from the Phase 1 UNIVERSAL trial in heavily pretreated, relapsed&#47;refractory MM patients, which demonstrated for the first time that an allogeneic CAR T therapy directed at BCMA can achieve clinical responses while eliminating the need for bridging therapy or delays in treatment associated with manufacturing.</font></div><div><font><br></font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">Patient dosing has begun in the portion of the UNIVERSAL trial investigating ALLO-715 in combination with nirogacestat in patients with relapsed&#47;refractory MM. Nirogacestat is an investigational gamma secretase inhibitor being developed by SpringWorks Therapeutics.</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">ALLO-605 TurboCAR&#8482; IGNITE Trial</font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">The FDA cleared the Investigational New Drug (IND) application to evaluate ALLO-605, the first TurboCAR T cell therapy, for use in relapsed&#47;refractory MM. TurboCAR technology allows cytokine activation signaling to be engineered selectively into CAR T cells to potentially improve efficacy, overcome exhaustion, and reduce cell dose requirements. The Phase 1 IGNITE trial will evaluate escalating doses of ALLO-605 beginning in mid-2021. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Solid Tumor Program</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">ALLO-316 TRAVERSE Trial</font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#9702;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.46pt">Patient dosing has begun in the Phase 1 TRAVERSE trial examining safety, tolerability, anti-tumor efficacy, pharmacokinetics and pharmacodynamics of ALLO-316, Allogene&#8217;s first CAR T candidate for solid tumors, in patients with advanced or metastatic clear cell renal cell carcinoma.</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;padding-left:14.5pt">Expanded TurboCAR Platform</font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#9702;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.46pt">In April 2021, at the American Association for Cancer Research (AACR) Annual Meeting, the Company reported on pre-clinical data that expands the TurboCAR technology platform to address the biology of solid tumor oncology. TurboCARs were engineered to confer cytokine signaling that is inducible upon binding to PDL1 in the tumor microenvironment or when stimulated with an anti-PD1 antibody while acting as a dominant negative for PDL1 and PDL2 immunosuppressive signaling. These TurboCARs are designed to overcome the challenges in solid tumors associated with an immuno-suppressive tumor microenvironment (TME) by turning negative signals into positive signals.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">First Quarter Financial Results</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">Research and development expenses were $55.2 million for the first quarter of 2021, which includes $7.9 million of non-cash stock-based compensation expense.</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">General and administrative expenses were $16.4 million for the first quarter of 2021, which includes $8.9 million of non-cash stock-based compensation expense.</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">Net loss for the first quarter of 2021 was $33.0 million, or $0.25 per share, including non-cash stock-based compensation expense of $16.8 million.</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">The Company had $964.2 million in cash, cash equivalents, and investments as of March 31, 2021.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2021 Financial Guidance</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Allogene continues to expect full year GAAP Operating Expenses to be between $300 million and $330 million including estimated non-cash stock-based compensation expense of $80 million to $90 million and excluding any impact from potential new business development activities.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Conference Call and Webcast Details</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Allogene will host a live conference call and webcast today at 2&#58;00 p.m. Pacific Time &#47; 5&#58;00 p.m. Eastern Time to discuss financial results and provide a business update. To access the live conference call by telephone, please dial 1 (866) 940-5062 (U.S.) or 1 (409) 216-0618 (International). The conference ID number for the live call is 9435559. The webcast will be made available on the Company's website at </font><font style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">www.allogene.com</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> under the Investors tab in the News and Events section. Following the live audio webcast, a replay will be available on the Company's website for approximately 30 days. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Virtual CD19 Forum</font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additional information on the Company&#8217;s May 19 Virtual CD19 Forum will be made available in a separate press release and on the Company's website at </font><font style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">www.allogene.com</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> under the Investors tab in the </font><font style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">News and Events section</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Materials presented will be available on the Allogene website prior to the start of the event.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">About Allogene Therapeutics</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Allogene Therapeutics, with headquarters in South San Francisco, is a clinical-stage biotechnology company pioneering the development of allogeneic chimeric antigen receptor T cell (AlloCAR T&#8482;) therapies for cancer. Led by a management team with significant experience in cell therapy, Allogene is developing a pipeline of &#8220;off-the-shelf&#8221; CAR T cell therapy candidates with the goal of delivering readily available cell therapy on-demand, more reliably, and at greater scale to more patients. For more information, please visit </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">www.allogene.com</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and follow &#64;AllogeneTx on Twitter and LinkedIn.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cautionary Note on Forward-Looking Statements </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This press release contains forward-looking statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The press release may, in some cases, use terms such as &#34;predicts,&#34; &#34;believes,&#34; &#34;potential,&#34; &#34;proposed,&#34; &#34;continue,&#34; &#34;estimates,&#34; &#34;anticipates,&#34; &#34;expects,&#34; &#34;plans,&#34; &#34;intends,&#34; &#34;may,&#34; &#34;could,&#34; &#34;might,&#34; &#34;will,&#34; &#34;should&#34; or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Forward-looking statements include statements regarding intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things&#58; the timing and ability to progress the ALPHA, ALPHA2, UNIVERSAL and TRAVERSE trials, including progressing to the Phase 2 portion of the ALPHA2 trial, and present any data from the trials&#59; clinical outcomes, which may materially change as patient enrollment continues and more patient data become available&#59; the timing and ability to initiate a clinical trial of ALLO-605&#59; the ability of ALLO-605 to improve efficacy, overcome exhaustion, and reduce cell dose requirements&#59; the ability to expand the TurboCAR platform&#59; the ability to manufacture AlloCAR T&#8482; therapies, including for use in clinical trials, the potential benefits of AlloCAR T&#8482; therapy and the 2021 financial guidance. Various factors may cause differences between Allogene&#8217;s expectations and actual results as discussed in greater detail in Allogene&#8217;s filings with the Securities and Exchange Commission (SEC), including without limitation in its Form 10-Q for the quarter ended March 31, 2021. Any forward-looking statements that are made in this press release speak only as of the date of this press release. Allogene assumes no obligation to update the forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">AlloCAR T&#8482; and TurboCAR T&#8482; are trademarks of Allogene Therapeutics, Inc. </font></div><div><font><br></font></div><div><font style="color:#0a0a0a;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Allogene&#8217;s AlloCAR T programs utilize the Cellectis TALEN&#174; technology. ALLO-501 and ALLO-501A are anti-CD19 allogeneic CAR T (AlloCAR T&#8482;) therapies being jointly developed under a collaboration agreement between Servier</font><font style="color:#0a0a0a;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">1</font><font style="color:#0a0a0a;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and Allogene based on an exclusive license granted by Cellectis to Servier. Servier grants to Allogene exclusive rights to ALLO-501 and ALLO-501A in the U.S. while Servier retains exclusive rights for all other countries. The anti-BCMA and anti-CD70 AlloCAR T programs are licensed exclusively from Cellectis by Allogene and Allogene holds global development and commercial rights to these AlloCAR T programs.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">_____________________________________________________________________________________________________</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">&#185; Servier is an independent international pharmaceutical company governed by a non-profit foundation, with its headquarters in France (Suresnes).</font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="iecbbf3d2c20a41eab9b6439a89ecb2eb_4"></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ALLOGENE THERAPEUTICS, INC.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SELECTED FINANCIAL DATA</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(unaudited&#59; in thousands, except share and per share data)</font></div><div id="iecbbf3d2c20a41eab9b6439a89ecb2eb_7"></div><div style="margin-top:10pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">STATEMENTS OF OPERATIONS</font></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.245%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.935%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.936%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31,</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collaboration revenue - related party</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,345&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses&#58;</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</font></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55,183&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42,042&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,363&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,641&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</font></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71,546&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57,683&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss from operations</font></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(33,201)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(57,683)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income (expense), net&#58;</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest and other income, net</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">511&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,261&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other expenses</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(325)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(58)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total other income (expense), net</font></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">186&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,203&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</font></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(33,015)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(54,480)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss per share, basic and diluted</font></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.25)</font></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.50)</font></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average number of shares used in computing net loss per share, basic and diluted</font></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">132,165,014&#160;</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">108,963,522&#160;</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><font><br></font></div><div id="iecbbf3d2c20a41eab9b6439a89ecb2eb_10"></div><div style="margin-top:10pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SELECTED BALANCE SHEET DATA</font></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:54.894%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.537%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.539%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of March 31, 2021</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31, 2020</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash, cash equivalents and investments</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">964,154&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,032,118&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,179,044&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,227,829&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">109,265&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">148,212&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stockholders&#8217; equity</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,069,779&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,079,617&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Allogene Media&#47;Investor Contact&#58;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Christine Cassiano</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Chief Communications Officer</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(714) 552-0326</font></div><div><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Christine.Cassiano&#64;allogene.com</font></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>3
<FILENAME>allo-20210505.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:093e9ea0-7f33-48b7-ab74-020f9c8ee32d,g:99b413ce-972b-4416-8868-b52d8e8c6c1a-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:allo="http://allogene.com/20210505" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://allogene.com/20210505">
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2019-01-31" schemaLocation="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="allo-20210505_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="allo-20210505_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="allo-20210505_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="allo-20210505_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="DocumentandEntityInformationDocument" roleURI="http://allogene.com/role/DocumentandEntityInformationDocument">
        <link:definition>0001001 - Document - Document and Entity Information Document</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>4
<FILENAME>allo-20210505_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:093e9ea0-7f33-48b7-ab74-020f9c8ee32d,g:99b413ce-972b-4416-8868-b52d8e8c6c1a-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://allogene.com/role/DocumentandEntityInformationDocument" xlink:type="simple" xlink:href="allo-20210505.xsd#DocumentandEntityInformationDocument"/>
  <link:calculationLink xlink:role="http://allogene.com/role/DocumentandEntityInformationDocument" xlink:type="extended"/>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>5
<FILENAME>allo-20210505_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:093e9ea0-7f33-48b7-ab74-020f9c8ee32d,g:99b413ce-972b-4416-8868-b52d8e8c6c1a-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://allogene.com/role/DocumentandEntityInformationDocument" xlink:type="simple" xlink:href="allo-20210505.xsd#DocumentandEntityInformationDocument"/>
  <link:definitionLink xlink:role="http://allogene.com/role/DocumentandEntityInformationDocument" xlink:type="extended" id="i8ae4802f5c4d4dfe9dee6bfd5275cc1b_DocumentandEntityInformationDocument"/>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>6
<FILENAME>allo-20210505_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:093e9ea0-7f33-48b7-ab74-020f9c8ee32d,g:99b413ce-972b-4416-8868-b52d8e8c6c1a-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_dei_WrittenCommunications_03c3256a-d911-489e-b49b-2da7c530945b_terseLabel_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Written Communications</link:label>
    <link:label id="lab_dei_WrittenCommunications_label_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Written Communications</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_WrittenCommunications"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_WrittenCommunications" xlink:to="lab_dei_WrittenCommunications" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_PreCommencementTenderOffer_8a99059b-c017-4401-b15a-f60323e202d0_terseLabel_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_PreCommencementTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementTenderOffer" xlink:to="lab_dei_PreCommencementTenderOffer" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_d4f48b7f-e76c-4bfc-8951-750c8e23ac86_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_ed434933-0936-4caf-94ae-a23b15029b33_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SolicitingMaterial_0955fa56-80c5-4e01-bcb0-23df09fe3960_terseLabel_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Soliciting Material</link:label>
    <link:label id="lab_dei_SolicitingMaterial_label_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Soliciting Material</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SolicitingMaterial"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SolicitingMaterial" xlink:to="lab_dei_SolicitingMaterial" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_468fc930-9c3a-42db-a927-44951cb79d4f_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_52c80a73-e19c-47a2-972b-deb559c63b26_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_656785d6-78ae-4517-85b1-3a1690268dca_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_fc877705-1243-4026-8d22-b3e4f5fc68c0_terseLabel_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_8125db0d-963f-41ff-b05f-0d117680ade5_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_78e172a6-5b83-4763-9e13-60f7c896b9aa_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_c2aff2d3-72f7-4419-af3d-e9b77bd31c9f_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_403aad66-b648-45a3-913f-59fe16ae5ba4_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_6753857e-1ef0-4061-ac07-3aca08bc943d_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_0ecee880-32f7-4fa5-9545-154f6ea7f934_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_7308e449-b6f7-40bd-9fc3-7a1ab2b05714_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_a5b49547-cdd7-40fe-a993-1de926f4ae32_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_f1745490-53c4-44e6-847d-087895606cd6_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_cf53bd8f-1e26-49db-87c8-22fc311e2f2d_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_bf0e4c38-666b-48bd-8ca0-43ec29620888_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_506026d2-bd0c-46ba-bf02-630cec371b2f_terseLabel_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementIssuerTenderOffer" xlink:to="lab_dei_PreCommencementIssuerTenderOffer" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_166335ef-d095-464c-a8a8-026fee9b6b51_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_95cb9d83-4ffb-4518-93c4-7544da019681_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>7
<FILENAME>allo-20210505_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:093e9ea0-7f33-48b7-ab74-020f9c8ee32d,g:99b413ce-972b-4416-8868-b52d8e8c6c1a-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://allogene.com/role/DocumentandEntityInformationDocument" xlink:type="simple" xlink:href="allo-20210505.xsd#DocumentandEntityInformationDocument"/>
  <link:presentationLink xlink:role="http://allogene.com/role/DocumentandEntityInformationDocument" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_1cbd6222-e0eb-4dcb-87e8-cad83f30be26" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_39a4088c-b379-499e-83a5-264fa4ed6e74" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1cbd6222-e0eb-4dcb-87e8-cad83f30be26" xlink:to="loc_dei_DocumentType_39a4088c-b379-499e-83a5-264fa4ed6e74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_2ccac980-343c-4140-a7f7-df645ef3677b" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1cbd6222-e0eb-4dcb-87e8-cad83f30be26" xlink:to="loc_dei_DocumentPeriodEndDate_2ccac980-343c-4140-a7f7-df645ef3677b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_7d211991-ffb9-4a4b-91dd-3117c6ad8485" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1cbd6222-e0eb-4dcb-87e8-cad83f30be26" xlink:to="loc_dei_EntityRegistrantName_7d211991-ffb9-4a4b-91dd-3117c6ad8485" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_4e8195d1-4de9-4d0b-bb9e-6ca6c49d982d" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1cbd6222-e0eb-4dcb-87e8-cad83f30be26" xlink:to="loc_dei_EntityCentralIndexKey_4e8195d1-4de9-4d0b-bb9e-6ca6c49d982d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_54a02dd1-6553-4f94-935d-43eecfc5327e" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1cbd6222-e0eb-4dcb-87e8-cad83f30be26" xlink:to="loc_dei_AmendmentFlag_54a02dd1-6553-4f94-935d-43eecfc5327e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_7dfac0f9-163c-4af4-83c3-11f0263d8958" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1cbd6222-e0eb-4dcb-87e8-cad83f30be26" xlink:to="loc_dei_EntityIncorporationStateCountryCode_7dfac0f9-163c-4af4-83c3-11f0263d8958" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_f8529e91-ce1f-475c-978b-8a4025fa0500" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1cbd6222-e0eb-4dcb-87e8-cad83f30be26" xlink:to="loc_dei_EntityFileNumber_f8529e91-ce1f-475c-978b-8a4025fa0500" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_69e67f1f-41ce-475b-9bb5-875b84efa88f" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1cbd6222-e0eb-4dcb-87e8-cad83f30be26" xlink:to="loc_dei_EntityTaxIdentificationNumber_69e67f1f-41ce-475b-9bb5-875b84efa88f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_6e2ad653-b93c-4dae-8e2f-965e089db5ee" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1cbd6222-e0eb-4dcb-87e8-cad83f30be26" xlink:to="loc_dei_EntityAddressAddressLine1_6e2ad653-b93c-4dae-8e2f-965e089db5ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_27a56dc1-c870-41e4-95cb-3ebecddda65d" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1cbd6222-e0eb-4dcb-87e8-cad83f30be26" xlink:to="loc_dei_EntityAddressCityOrTown_27a56dc1-c870-41e4-95cb-3ebecddda65d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_25ddeb02-d068-4a5c-b377-4ff746cef979" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1cbd6222-e0eb-4dcb-87e8-cad83f30be26" xlink:to="loc_dei_EntityAddressStateOrProvince_25ddeb02-d068-4a5c-b377-4ff746cef979" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_62dd2ff9-cddc-4f03-ad15-3868c9496c9b" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1cbd6222-e0eb-4dcb-87e8-cad83f30be26" xlink:to="loc_dei_EntityAddressPostalZipCode_62dd2ff9-cddc-4f03-ad15-3868c9496c9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_a8eff372-ef20-42f3-9ae3-bf4af095bc13" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1cbd6222-e0eb-4dcb-87e8-cad83f30be26" xlink:to="loc_dei_CityAreaCode_a8eff372-ef20-42f3-9ae3-bf4af095bc13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_8ab1c89b-84c5-44c2-b9b2-8ae9635c04ec" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1cbd6222-e0eb-4dcb-87e8-cad83f30be26" xlink:to="loc_dei_LocalPhoneNumber_8ab1c89b-84c5-44c2-b9b2-8ae9635c04ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications_188b199d-3e71-4bf1-9528-3ad0ff0d6a37" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_WrittenCommunications"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1cbd6222-e0eb-4dcb-87e8-cad83f30be26" xlink:to="loc_dei_WrittenCommunications_188b199d-3e71-4bf1-9528-3ad0ff0d6a37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial_b8633354-1304-455d-aef8-660140173b97" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SolicitingMaterial"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1cbd6222-e0eb-4dcb-87e8-cad83f30be26" xlink:to="loc_dei_SolicitingMaterial_b8633354-1304-455d-aef8-660140173b97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer_2b5cdc32-2772-4691-8772-b6e7c29a9356" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_PreCommencementTenderOffer"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1cbd6222-e0eb-4dcb-87e8-cad83f30be26" xlink:to="loc_dei_PreCommencementTenderOffer_2b5cdc32-2772-4691-8772-b6e7c29a9356" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer_286b09e2-b60d-467c-868b-93a80146a0a8" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1cbd6222-e0eb-4dcb-87e8-cad83f30be26" xlink:to="loc_dei_PreCommencementIssuerTenderOffer_286b09e2-b60d-467c-868b-93a80146a0a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_0296bc5d-a781-4ec6-9780-3fcf1f78c56a" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1cbd6222-e0eb-4dcb-87e8-cad83f30be26" xlink:to="loc_dei_Security12bTitle_0296bc5d-a781-4ec6-9780-3fcf1f78c56a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_2b4a9b53-4745-425e-a139-8d2cbc55c8c5" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1cbd6222-e0eb-4dcb-87e8-cad83f30be26" xlink:to="loc_dei_TradingSymbol_2b4a9b53-4745-425e-a139-8d2cbc55c8c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_b0f336b4-4409-4d31-8620-efba28f8406e" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1cbd6222-e0eb-4dcb-87e8-cad83f30be26" xlink:to="loc_dei_SecurityExchangeName_b0f336b4-4409-4d31-8620-efba28f8406e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_ced84fd2-f2c1-4470-9a15-6f69770c9784" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1cbd6222-e0eb-4dcb-87e8-cad83f30be26" xlink:to="loc_dei_EntityEmergingGrowthCompany_ced84fd2-f2c1-4470-9a15-6f69770c9784" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>g725933allogenea061.jpg
<TEXT>
begin 644 g725933allogenea061.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  (! 0(! 0(" @(" @(" P4# P,#
M P8$! ,%!P8'!P<&!P<("0L)" @*" <'"@T*"@L,# P,!PD.#PT,#@L,# S_
MVP!# 0(" @,# P8# P8," <(# P,# P,# P,# P,# P,# P,# P,# P,# P,
M# P,# P,# P,# P,# P,# P,# P,# S_P  1"  P ,P# 2(  A$! Q$!_\0
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M[Z7_ .AWU0_\%+#_ ,;^OV>?^O;0O_3A?5)^WC,L/_!Q/\"6;[OD:2OXF2^
M_G6U/['_ %[9PXQ_O,1_V%4_RB4_^"H!US_@H7_P5E\"_LTMJEWH_@?P^(;W
M4!:N"TTKVYNKBX*GY3(D 6&(L&\LO(P!W$5]H>*O^"-O[./B;X3R>$5^&>BZ
M7;^08H=3L%,>K6[8P)1='=(S@\_O"RD]5()%?'G_  5N\#^,/V%/^"B'@O\
M:PT#2;CQ!X3S;VNOQ193[&\<?V9XI7QB-+BW8".0Y42H0V,H&]]\7?\ !PI^
MSOH?PBD\1Z=K&N:QK#0,T'AP:7+!?&7;D1R.P\F,9X+[V  )&[@'FJ1KRI4O
MJM[6Z?S=;GIX6IEM/&8U9QRJ;EISVUIV7+RWZ;Z+6_F>*?\ !!7XB^)_@9^T
MC\8?V8_$.H2:MIW@FXNK[2)R=BV[6]V+>X\M,MLCN%E@G$8;$;"3[Q<D>3?\
M$L?@1IO_  6/_:_^)WQO^+UO<:QHNFR6LECH<[M]GD:Y\U[>V=@P/DVMO&H\
ML8$CS!B>&#^W?\$%OV>_&WC'XH?$K]IKQ[8R:7<_$YI4T:!HV3[7%<7 NKBY
M0.-WV?*P1P-G+*DAY4HQ\)_9 ^+TW_! O]M?QU\-?B/I.K2?#?Q>(?[*U>"!
MIG:VMFE%I>1+D"5?*G\JX5,NCJG4+A^F5W4K*C_$LMN_VK?\ \BC%0PN!GF"
M?U93G\6R6OLN>_1=+Z;7/J'_ (*W?\$J/A9+^R5XI\<> _".C^!O%W@+3Y=6
MAGT*V6QBOK>-?W\$T<>%8-%OPV-V>,D,0?+OV$/VDM2_9._X-_/%GC;0Y(H=
M>T_5=1M=+ED02+!<SW,<,<FT\$IOW@$$$J 016U_P4W_ ."RO@'XY?LU^)OA
MK\&I=6\;^(/%NE7"ZC>6]A-;VNBZ;&@DNYG,BJ6/E!EP!M7)+,#M#0_\$T/V
M:)/VO_\ @A/XK^'MK<V]GJ6O:MJ9T^><'RHKN*>*6'?CD(7158@$A6)P<8.<
M54CA5]:O;G6CWM^=CKK2PU3.IO*+<[H3UCLY75K-:7VN_2YX/_P2[\0_L=_#
M/X73^*/CIK6E^+/B;X@O9[BZMM?TVZU6+38_,;&0T;)+/*?WLDKEV)8#(P<\
MG^WO\7O@/\#?CCX%^,G[)/BBUTGQ5HU[(^J:':VES;V7"ADE1'50L,BB6":(
M-M=9(RJH58MW_P#P3H_:I^ ?[./A74/A%^TY\(/#.A^./!]Y+&NK:QX-MK^X
MFC=BXAN2(FE#H2=DGSI)&4(;U^C?@9^UY^Q[^TW^UA8_"OP/^SSX?\21ZC:M
M*-=M_A_8?8[=AG>9HVC$L< &T>>R[=SA<<@GJJS<*TJKC-QUZKE:^[8\?!T8
M8C TL)&M1A4NK>[)55--7O[U^:^[M;Y'B_\ P<O>/;+QY\+/V=_%%I&SZ;K.
MF:UJT,;CYFBE@TR55/OM8"OMK]E[_@C]\)?A%\-I(?''A7P_\3?'>O;[SQ-X
MCU^S6_FU&^F)DN)(C*"8E,C-@KASU8EB37Q;_P '4.F6OA_P)\$[*RM[>RL;
M&R\100001B.&WB2'3E5%48"JJ@  < "OV&S7F8BM*.#HJ#LGS?F?6Y7@*-;/
M<=4Q$5*4?9+576L-;)_\/;0_(/\ 8-\!I^Q-_P %[O&WPL\(W$UOX+\06-PC
M6!D9T6 6RWMLC;B2S0.TB(S98)*XS\S9\R_;&^.G@+]J;_@L-K%E\>?$USI7
MPA^%\]QI%E8QB=EG,.P/$HB#,K7$^6DD7#-'"B[AM3'M/A^5HO\ @YYO]O\
M%8R*>.W]C+7"_M]?"M?^";W_  4ZNOC1XN^'.G_$SX,_$B:26^@N],AO(;2>
M<()HOWZM%'<K(BRQ;RHE5V0,#OV^C"476BW\4J:MT;?DWUL?*XBG4C@)TZ=O
M94\3)233<5'I=*SY4WJCK?VE/BO_ ,$[_C_\&+[POI4GASP+K'V9H](UW1_"
M%S:W&G7&/W<DOEQ*;B,,!O20G<I8 JQ##D/^"4G_  60_P"&=/V3[?P3XSMI
MM:D\/ZA);Z0[W!W6E@8H62WS@Y6.1I@OHFQ0 %%>F?%W_@J!^PAX#^'DFK>'
M_A%X)\7ZPP!ATJ/P%9V!R2 ?-FG@"1@>HW$]@<U]K? #X$?!WXM?"'0_%.F_
M OPMX1M?$%NMZ-*UGP79:?J%KNXQ-"$.UL =SD8[5RU:D:='DK4Y6;TYFM_+
M2Y[.#PM?%8[ZQ@,314XQL_9Q=FG:W-[S3M;3JCIOCK\%/&7Q*^*'PWUKPW\3
M-5\$Z/X/U.6]UW1K73TN8O%L#! MO*[.IB"[7Y"N/WA^7(5A\A_%WX3VMKH'
M[75C>?LB[_#LDECJUM/I>K21W'Q*G6264RH(D9X6A=WF_<JQS*X*ER2WW3\9
M?@UX9_:#^&FK>#O&6D6^O>&==B$-_83LRQW*!U< E2&&&53P1TKDOC7\"?%'
MQ*^-7PS\3:)\1M<\(Z-X'O+NYUG0;* 26_BU)DC6.*=BXV+$48@[7SYK< @,
M/G9144YP7O\ 1]8O175W967].Y^MX?$2K2AA<5-+#I/FC:T:B3E/V=3DCS24
MI62;;<6UK&,3X-O="\?:=\$/@O\ $;6(]'^"G[+_ (7\-+;^-?AIKD$NHF=!
M=3*4:WEM_,NFNU>W,?F;'C8EB"?F:O-X?^)$/[-OQH\>M%I?QZ_9M\8Z5'%X
M#^'OA^VET_[);->1^4RQ0P"6T%E$KJZ1"1Y73?\ (5+'WK5_@=X/U%OVCOC!
MX?;QQ\?!XHAGT#4?AS?W132Y;S37$;VL$<L6=RR(0D@#[ 7\O<6YO:?\"/!_
MA_QU^SK\7=<O/&OP7FTK2K?PII/PVL;G=H]O>WR.PM)HX8S\^YF5W.P2&&$O
MM*8.WM*KG[+F5^3XN7WN:][WVO?^K''&AEZP:S!T&X?66_9>W_<^RY5'DY;\
M]N7KM;2_,>?_  J^%L+>*OV3;6Q_9%CL?#-AI4^HOJ>HZH\EW\.+F1A,5DWH
M&F<R*LF9E5F:0$+&Z,*^L/V>?@GXR^%/BWQ_?>*OB9JWC^R\5Z])JFBV-YI\
M=K'X7M#G;91,K,9%&0-QV@[!\@)9F9\"/@'XH^%OQ,^)6M:]\2O$7CC2O'&J
MQWVDZ1J$"1V_A2%496MX&4DLK%ADX48C3Y=V]W[7X0_"/PY\!?AEHO@WPAI4
M.A^&?#MJMEIMA"S-':PKT0%B6('N2:QC%22G-6EU?=[7=G9MK^DSLQ&(G1<\
M+AZBE0:7+&SM3CI+V=/GCS149-IM-7:>LD[FUK&C6^OZ/<Z?>1B:TO(7@GC)
M($B,I5E..>02.*X?X$?LH_#?]F"'48_A[X+\/>#TU<Q&^&F6BP&[\H,(@Y')
M"!WVCH-[8ZFO0J*VYFE9/0\N5&$IJHXJZV=M5Z,*\Z^-/[(_PS_:,U33[[QU
MX'\-^*KS28WALI]1LEFEMD=E9E5CR 64'V(R,9->BT41DXN\0JT85(\E1)KL
MU=' ^,_V6_AW\1/BII/CC7/!WA_5?&&AK$NGZQ<VBO>68B=GCV/U7:SN1Z%C
M3O$_[,'P]\:?%?3?'6K>#?#VI>,M'6-;'6;BR22\LQ&6*>7(1E=I=L8_O&N\
MHH]I+N0\+1=[P6KN]%OW]?,@U+3;?5[*:VNH8KBWN(VBEBE0/'*C##*RG@J1
MP0>#7BVD_P#!-3X Z%XS_P"$@M?@_P##^'5 _F*XT:$Q1M_>6$CRU(Z@JHQV
MKW"BG&I./PMH*V%HU6G5@I6VND[>EQJIMS_M=:^/O^"M/[87PX_9;TGP-IOQ
M>^%C_$;X>^,)[U+FZ^R0W2:+=P+#Y/[N90A>5)I\,)4D A;:K@ML^PZKZEI=
MOJ]E-;74,-Q;W"&.6*5 \<BGJ&4\$'T-.C-0FI25UZV_$RQ^'J5Z$J5*2BWU
M:4EOU3W3V/Q?_:*_X*5?L_ZC^SQXB^$?[+OPDO(?%GQ4MQI%U)9Z EK<&%C\
MR!5WW%U)MW*J ;%WLVX8PWUI^R%X(^)7_!,K]@KX7^&8_"/A?Q-XH\5^(1!J
MMEJGB6;1UTB[U&8?9XM\-G=B79PLK#;M*G:),U]H>!O@[X3^&#W#>&?#/A[P
MZUX09SI>FPV9G[_,8U7=^-:'B#P9I?BR.S75+"UU!=/NXKZV6XC$@M[B([HY
M5ST=3R".0:Z,9BO:4O8T;QUO=N[;^X\_A_)EA,?''YARU+1Y5"*Y(J+=W:SO
M=O6]UV/CC]I'X[_"GXU^+[KP]X\^#ND>,M0\.ZSKFCK/J=DY6&WT[2[G4/,@
MO7MA&6E,*QFW27='O+G=L(K'\#?M:Z9^R5^RYX;\4:)\&/A;\-+3QEJA@>V7
M5]3TG3X+6/3)+[[5=7#:$L[LH5T&VWDBP=WGXRH^S+OX+^$[\M]H\.Z/-NO+
MG4&$EJC!KBXA>">4@C!:2*21&/\ $KL#P:Q_ O[+'P[^&6B0Z;H/@W0=-L+>
MXDNHH([53''));_978!LXW0$Q$="A(Z5Y4OK7+R*>G_#=/O^\^YIU,AC-5GA
M&YZ7?-J_BO[VC5[QMH]CYT^+7[0OP@_:'^/OPI^&?Q0^&/AK4M8\5:!%J,EC
MXN%G+?>%;K4H'EAT_P"R2!GDDD6RN4G:,@0M';!@PG4K1\$_\%7_ !)XY^'6
MJ:U9?"[3YIH;_2;+3Q!X@O[FSN6OKF[A:&66/2FE6Z@%KYDD-M!<@+/%^\YK
MZK\/_ ;P7X4\+PZ)IOA7P_9Z1;R64T=G%81K"DEE'!':/MQC= EM;K&W5!!&
M 1M&(O$G[//@CQ?\-K?P?J7A?1;SPM9M&]OI<EL/LUNT;;D9%_A*MR".E)PQ
M#^WWZ?=_F:T<5DD'=X5W?+=\SOHVY.R:U::BDWHE>]VV?.]K\6O"6C?%S7?&
M&I?!_P 'V?Q(T9O"<-YK-O+NOW_MV86AVSS6<-RJP+D8DC1I-I0K$0<;R?M;
M>(O$EUXCT/QI\-O"(T6'QS8_#TQVWB>35%OS=^67FEAFT^%1&L4T)V;GWL9%
M)4*'?UI/V3OAJGB3PSK'_"$^&VU;P;;I::)>-9(TVFQ(6,:1L1G",[LF<[#(
MY7!9B>@E^$?AF>::230=*>2XU2/7)6-LF9+^,*L=T>.95"( _4;1Z57+7>KE
MM_7;^K&'MLI@FH8?XM]6M?=O:TM;V;=[_%;HF_C/X*:3X9TOX;W/QG^'_P"R
MC\-UM+RWCU/P?<Z3=)+K%TK7:0B2XMX]/9[%EC8SE;4W<BI&Z;?,Q&WUQ\ /
MBI_PNWX0:+XH\O389-4C?SH;"ZENK>"6.1XI(UDE@@E)5T92)(8G4@JR*016
M+<_L3?"*\U'Q)=R_#?P8]UXNS_;$ITF'??$S"<LQV\,9U68E<$RJ)"=X#5W'
M@GP!HOPW\*V.AZ!I=EH^CZ;'Y5K9VD0BA@7))PHXY)))ZDDDY))JH^WE*]65
@]/Q^XYL3_9<:3A@:/LVY75E9*-MG[SN[];*^NU[+_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>allo-20210505_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="allo-20210505.xsd" xlink:type="simple"/>
    <context id="i259d1a27ddae4f849a0c7f0668bff90e_D20210505-20210505">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
        </entity>
        <period>
            <startDate>2021-05-05</startDate>
            <endDate>2021-05-05</endDate>
        </period>
    </context>
    <dei:EntityCentralIndexKey
      contextRef="i259d1a27ddae4f849a0c7f0668bff90e_D20210505-20210505"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YzkyMzhhOGY0MDQ1ODg4Njk1NjJkZTgxOTI1MmFhL3NlYzo4OWM5MjM4YThmNDA0NTg4ODY5NTYyZGU4MTkyNTJhYV80L2ZyYWc6OWExNTI0NWJiMjUzNDJhYWE1YzkyZDZiYmMzZjc3N2QvdGFibGU6MGEzMzhiZTc0YWRjNGI2MTgzOWZjM2E4MzQ4NDRiMWEvdGFibGVyYW5nZTowYTMzOGJlNzRhZGM0YjYxODM5ZmMzYTgzNDg0NGIxYV8xLTEtMS0xLTA_378bb10a-7a03-4490-a120-a321b1cd39c4">0001737287</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag
      contextRef="i259d1a27ddae4f849a0c7f0668bff90e_D20210505-20210505"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YzkyMzhhOGY0MDQ1ODg4Njk1NjJkZTgxOTI1MmFhL3NlYzo4OWM5MjM4YThmNDA0NTg4ODY5NTYyZGU4MTkyNTJhYV80L2ZyYWc6OWExNTI0NWJiMjUzNDJhYWE1YzkyZDZiYmMzZjc3N2QvdGFibGU6MGEzMzhiZTc0YWRjNGI2MTgzOWZjM2E4MzQ4NDRiMWEvdGFibGVyYW5nZTowYTMzOGJlNzRhZGM0YjYxODM5ZmMzYTgzNDg0NGIxYV8yLTEtMS0xLTA_19cd2edf-d3dc-4f94-b1ff-821e9d2bc469">false</dei:AmendmentFlag>
    <dei:DocumentType
      contextRef="i259d1a27ddae4f849a0c7f0668bff90e_D20210505-20210505"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YzkyMzhhOGY0MDQ1ODg4Njk1NjJkZTgxOTI1MmFhL3NlYzo4OWM5MjM4YThmNDA0NTg4ODY5NTYyZGU4MTkyNTJhYV8xL2ZyYWc6ZjFiOGEyYTFmZjJlNGQzMWE3M2M1MzVlOWEzNDhhYzUvdGV4dHJlZ2lvbjpmMWI4YTJhMWZmMmU0ZDMxYTczYzUzNWU5YTM0OGFjNV8xNTE1_5328b475-39b2-432c-b53e-1f18c2a70f27">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate
      contextRef="i259d1a27ddae4f849a0c7f0668bff90e_D20210505-20210505"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YzkyMzhhOGY0MDQ1ODg4Njk1NjJkZTgxOTI1MmFhL3NlYzo4OWM5MjM4YThmNDA0NTg4ODY5NTYyZGU4MTkyNTJhYV8xL2ZyYWc6ZjFiOGEyYTFmZjJlNGQzMWE3M2M1MzVlOWEzNDhhYzUvdGV4dHJlZ2lvbjpmMWI4YTJhMWZmMmU0ZDMxYTczYzUzNWU5YTM0OGFjNV8yNjc_e950d86f-539a-47f7-95d3-a15224e12c9e">2021-05-05</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName
      contextRef="i259d1a27ddae4f849a0c7f0668bff90e_D20210505-20210505"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YzkyMzhhOGY0MDQ1ODg4Njk1NjJkZTgxOTI1MmFhL3NlYzo4OWM5MjM4YThmNDA0NTg4ODY5NTYyZGU4MTkyNTJhYV8xL2ZyYWc6ZjFiOGEyYTFmZjJlNGQzMWE3M2M1MzVlOWEzNDhhYzUvdGV4dHJlZ2lvbjpmMWI4YTJhMWZmMmU0ZDMxYTczYzUzNWU5YTM0OGFjNV8xNTEx_1cd1ea4e-f532-4380-88fd-10cabf85ad08">Allogene Therapeutics, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="i259d1a27ddae4f849a0c7f0668bff90e_D20210505-20210505"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YzkyMzhhOGY0MDQ1ODg4Njk1NjJkZTgxOTI1MmFhL3NlYzo4OWM5MjM4YThmNDA0NTg4ODY5NTYyZGU4MTkyNTJhYV8xL2ZyYWc6ZjFiOGEyYTFmZjJlNGQzMWE3M2M1MzVlOWEzNDhhYzUvdGFibGU6YTM3ZWJlZTA0ZDdlNDNiNjg2YzYxMzE3Y2QxZmViZTgvdGFibGVyYW5nZTphMzdlYmVlMDRkN2U0M2I2ODZjNjEzMTdjZDFmZWJlOF8wLTAtMS0xLTA_7536e7ef-fbd7-49f8-a9e4-286b62fd5a3d">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber
      contextRef="i259d1a27ddae4f849a0c7f0668bff90e_D20210505-20210505"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YzkyMzhhOGY0MDQ1ODg4Njk1NjJkZTgxOTI1MmFhL3NlYzo4OWM5MjM4YThmNDA0NTg4ODY5NTYyZGU4MTkyNTJhYV8xL2ZyYWc6ZjFiOGEyYTFmZjJlNGQzMWE3M2M1MzVlOWEzNDhhYzUvdGFibGU6YTM3ZWJlZTA0ZDdlNDNiNjg2YzYxMzE3Y2QxZmViZTgvdGFibGVyYW5nZTphMzdlYmVlMDRkN2U0M2I2ODZjNjEzMTdjZDFmZWJlOF8wLTEtMS0xLTA_b9f9797f-d0c2-4eab-a1c9-736e2700d963">001-38693</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber
      contextRef="i259d1a27ddae4f849a0c7f0668bff90e_D20210505-20210505"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YzkyMzhhOGY0MDQ1ODg4Njk1NjJkZTgxOTI1MmFhL3NlYzo4OWM5MjM4YThmNDA0NTg4ODY5NTYyZGU4MTkyNTJhYV8xL2ZyYWc6ZjFiOGEyYTFmZjJlNGQzMWE3M2M1MzVlOWEzNDhhYzUvdGFibGU6YTM3ZWJlZTA0ZDdlNDNiNjg2YzYxMzE3Y2QxZmViZTgvdGFibGVyYW5nZTphMzdlYmVlMDRkN2U0M2I2ODZjNjEzMTdjZDFmZWJlOF8wLTItMS0xLTA_59c319cf-700b-445a-933f-e3599174b4f4">82-3562771</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="i259d1a27ddae4f849a0c7f0668bff90e_D20210505-20210505"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YzkyMzhhOGY0MDQ1ODg4Njk1NjJkZTgxOTI1MmFhL3NlYzo4OWM5MjM4YThmNDA0NTg4ODY5NTYyZGU4MTkyNTJhYV8xL2ZyYWc6ZjFiOGEyYTFmZjJlNGQzMWE3M2M1MzVlOWEzNDhhYzUvdGV4dHJlZ2lvbjpmMWI4YTJhMWZmMmU0ZDMxYTczYzUzNWU5YTM0OGFjNV8xNTEz_6826b6cb-cea7-432e-9f81-89f70e5d2d37">210 East Grand Avenue</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="i259d1a27ddae4f849a0c7f0668bff90e_D20210505-20210505"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YzkyMzhhOGY0MDQ1ODg4Njk1NjJkZTgxOTI1MmFhL3NlYzo4OWM5MjM4YThmNDA0NTg4ODY5NTYyZGU4MTkyNTJhYV8xL2ZyYWc6ZjFiOGEyYTFmZjJlNGQzMWE3M2M1MzVlOWEzNDhhYzUvdGV4dHJlZ2lvbjpmMWI4YTJhMWZmMmU0ZDMxYTczYzUzNWU5YTM0OGFjNV8xNTA4_aea7ba84-7d4e-45e2-84ee-4db58d38be79">South San Francisco</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="i259d1a27ddae4f849a0c7f0668bff90e_D20210505-20210505"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YzkyMzhhOGY0MDQ1ODg4Njk1NjJkZTgxOTI1MmFhL3NlYzo4OWM5MjM4YThmNDA0NTg4ODY5NTYyZGU4MTkyNTJhYV8xL2ZyYWc6ZjFiOGEyYTFmZjJlNGQzMWE3M2M1MzVlOWEzNDhhYzUvdGV4dHJlZ2lvbjpmMWI4YTJhMWZmMmU0ZDMxYTczYzUzNWU5YTM0OGFjNV8xNTA5_c63d48bc-761f-46ab-993a-76a59f454133">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="i259d1a27ddae4f849a0c7f0668bff90e_D20210505-20210505"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YzkyMzhhOGY0MDQ1ODg4Njk1NjJkZTgxOTI1MmFhL3NlYzo4OWM5MjM4YThmNDA0NTg4ODY5NTYyZGU4MTkyNTJhYV8xL2ZyYWc6ZjFiOGEyYTFmZjJlNGQzMWE3M2M1MzVlOWEzNDhhYzUvdGV4dHJlZ2lvbjpmMWI4YTJhMWZmMmU0ZDMxYTczYzUzNWU5YTM0OGFjNV8xNTE2_24c0c699-d1b1-4169-be10-a8f7217ce45b">94080</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="i259d1a27ddae4f849a0c7f0668bff90e_D20210505-20210505"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YzkyMzhhOGY0MDQ1ODg4Njk1NjJkZTgxOTI1MmFhL3NlYzo4OWM5MjM4YThmNDA0NTg4ODY5NTYyZGU4MTkyNTJhYV8xL2ZyYWc6ZjFiOGEyYTFmZjJlNGQzMWE3M2M1MzVlOWEzNDhhYzUvdGV4dHJlZ2lvbjpmMWI4YTJhMWZmMmU0ZDMxYTczYzUzNWU5YTM0OGFjNV8xNTE3_e1271258-0602-499f-9864-39081b86b20f">650</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="i259d1a27ddae4f849a0c7f0668bff90e_D20210505-20210505"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YzkyMzhhOGY0MDQ1ODg4Njk1NjJkZTgxOTI1MmFhL3NlYzo4OWM5MjM4YThmNDA0NTg4ODY5NTYyZGU4MTkyNTJhYV8xL2ZyYWc6ZjFiOGEyYTFmZjJlNGQzMWE3M2M1MzVlOWEzNDhhYzUvdGV4dHJlZ2lvbjpmMWI4YTJhMWZmMmU0ZDMxYTczYzUzNWU5YTM0OGFjNV8xNTE0_a5013c48-8bcc-48f6-8fc4-88d931bb1636">457-2700</dei:LocalPhoneNumber>
    <dei:WrittenCommunications
      contextRef="i259d1a27ddae4f849a0c7f0668bff90e_D20210505-20210505"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YzkyMzhhOGY0MDQ1ODg4Njk1NjJkZTgxOTI1MmFhL3NlYzo4OWM5MjM4YThmNDA0NTg4ODY5NTYyZGU4MTkyNTJhYV8xL2ZyYWc6ZjFiOGEyYTFmZjJlNGQzMWE3M2M1MzVlOWEzNDhhYzUvdGFibGU6MWMyZWM3Y2ZhMGM1NGY0MDk4YWE2MmY5ZTIzODBmNzMvdGFibGVyYW5nZToxYzJlYzdjZmEwYzU0ZjQwOThhYTYyZjllMjM4MGY3M18wLTEtMS0xLTA_da72a612-3037-4d04-a715-c1cbef7cb4c4">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial
      contextRef="i259d1a27ddae4f849a0c7f0668bff90e_D20210505-20210505"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YzkyMzhhOGY0MDQ1ODg4Njk1NjJkZTgxOTI1MmFhL3NlYzo4OWM5MjM4YThmNDA0NTg4ODY5NTYyZGU4MTkyNTJhYV8xL2ZyYWc6ZjFiOGEyYTFmZjJlNGQzMWE3M2M1MzVlOWEzNDhhYzUvdGFibGU6MWMyZWM3Y2ZhMGM1NGY0MDk4YWE2MmY5ZTIzODBmNzMvdGFibGVyYW5nZToxYzJlYzdjZmEwYzU0ZjQwOThhYTYyZjllMjM4MGY3M18xLTEtMS0xLTA_475e0b72-3d94-4039-b2b1-31496f29e3d6">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer
      contextRef="i259d1a27ddae4f849a0c7f0668bff90e_D20210505-20210505"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YzkyMzhhOGY0MDQ1ODg4Njk1NjJkZTgxOTI1MmFhL3NlYzo4OWM5MjM4YThmNDA0NTg4ODY5NTYyZGU4MTkyNTJhYV8xL2ZyYWc6ZjFiOGEyYTFmZjJlNGQzMWE3M2M1MzVlOWEzNDhhYzUvdGFibGU6MWMyZWM3Y2ZhMGM1NGY0MDk4YWE2MmY5ZTIzODBmNzMvdGFibGVyYW5nZToxYzJlYzdjZmEwYzU0ZjQwOThhYTYyZjllMjM4MGY3M18yLTEtMS0xLTA_b8618381-265d-44c7-8f18-254eaa26baf3">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer
      contextRef="i259d1a27ddae4f849a0c7f0668bff90e_D20210505-20210505"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YzkyMzhhOGY0MDQ1ODg4Njk1NjJkZTgxOTI1MmFhL3NlYzo4OWM5MjM4YThmNDA0NTg4ODY5NTYyZGU4MTkyNTJhYV8xL2ZyYWc6ZjFiOGEyYTFmZjJlNGQzMWE3M2M1MzVlOWEzNDhhYzUvdGFibGU6MWMyZWM3Y2ZhMGM1NGY0MDk4YWE2MmY5ZTIzODBmNzMvdGFibGVyYW5nZToxYzJlYzdjZmEwYzU0ZjQwOThhYTYyZjllMjM4MGY3M18zLTEtMS0xLTA_cc59cfe3-041f-4825-971f-52a16a5828c4">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle
      contextRef="i259d1a27ddae4f849a0c7f0668bff90e_D20210505-20210505"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YzkyMzhhOGY0MDQ1ODg4Njk1NjJkZTgxOTI1MmFhL3NlYzo4OWM5MjM4YThmNDA0NTg4ODY5NTYyZGU4MTkyNTJhYV8xL2ZyYWc6ZjFiOGEyYTFmZjJlNGQzMWE3M2M1MzVlOWEzNDhhYzUvdGFibGU6NGMzMTk1MGYxNWZhNGFjNjgzYzQyY2FlMzA2MmMzMjUvdGFibGVyYW5nZTo0YzMxOTUwZjE1ZmE0YWM2ODNjNDJjYWUzMDYyYzMyNV8xLTAtMS0xLTA_09d3d340-274b-4001-a50f-105ffc52bfb2">Common&#160;Stock,&#160;$0.001&#160;par&#160;value&#160;per&#160;share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="i259d1a27ddae4f849a0c7f0668bff90e_D20210505-20210505"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YzkyMzhhOGY0MDQ1ODg4Njk1NjJkZTgxOTI1MmFhL3NlYzo4OWM5MjM4YThmNDA0NTg4ODY5NTYyZGU4MTkyNTJhYV8xL2ZyYWc6ZjFiOGEyYTFmZjJlNGQzMWE3M2M1MzVlOWEzNDhhYzUvdGFibGU6NGMzMTk1MGYxNWZhNGFjNjgzYzQyY2FlMzA2MmMzMjUvdGFibGVyYW5nZTo0YzMxOTUwZjE1ZmE0YWM2ODNjNDJjYWUzMDYyYzMyNV8xLTItMS0xLTA_b4272878-3c82-4e58-be0d-735ff9fa0f11">ALLO</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="i259d1a27ddae4f849a0c7f0668bff90e_D20210505-20210505"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YzkyMzhhOGY0MDQ1ODg4Njk1NjJkZTgxOTI1MmFhL3NlYzo4OWM5MjM4YThmNDA0NTg4ODY5NTYyZGU4MTkyNTJhYV8xL2ZyYWc6ZjFiOGEyYTFmZjJlNGQzMWE3M2M1MzVlOWEzNDhhYzUvdGFibGU6NGMzMTk1MGYxNWZhNGFjNjgzYzQyY2FlMzA2MmMzMjUvdGFibGVyYW5nZTo0YzMxOTUwZjE1ZmE0YWM2ODNjNDJjYWUzMDYyYzMyNV8xLTQtMS0xLTA_40a1c2e4-b69e-4546-98f3-f20dcb63c74b">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany
      contextRef="i259d1a27ddae4f849a0c7f0668bff90e_D20210505-20210505"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YzkyMzhhOGY0MDQ1ODg4Njk1NjJkZTgxOTI1MmFhL3NlYzo4OWM5MjM4YThmNDA0NTg4ODY5NTYyZGU4MTkyNTJhYV8xL2ZyYWc6ZjFiOGEyYTFmZjJlNGQzMWE3M2M1MzVlOWEzNDhhYzUvdGV4dHJlZ2lvbjpmMWI4YTJhMWZmMmU0ZDMxYTczYzUzNWU5YTM0OGFjNV8xNTEw_b9403d1f-7507-4b4f-bfad-c5f84c5084c4">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140457547087928">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document and Entity Information Document<br></strong></div></th>
<th class="th"><div>May 05, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">May  05,  2021<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Allogene Therapeutics, Inc.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001737287<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-38693<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">82-3562771<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">210 East Grand Avenue<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">South San Francisco<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">94080<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">650<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">457-2700<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common&#160;Stock,&#160;$0.001&#160;par&#160;value&#160;per&#160;share<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">ALLO<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>11
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
M" "1@J520;B?%E<$  ""$   &    'AL+W=O<FMS:&5E=',O<VAE970Q+GAM
M;*68VV[C-A"&K[=/0;A%T0))=/ Q6\> XSC;8'-P8[<+M.@%+8TM(A*IDE0<
MOWV'DB*Y6YERT9N8I#2_/LZ0,V3&.R%?5 2@R5L2<W75B;1./SJ."B)(J+H0
M*7!\LA$RH1J[<NNH5 (-<Z,D=GS7'3@)9;PS&>=C"SD9BTS'C,-"$I4E"97[
M:XC%[JKC==X'GMDVTF; F8Q3NH4EZ%_3A<2>4ZF$+ &NF.!$PN:J,_4^7OL]
M8Y"_\1N#G3IH$S.5M1 OIG,77G5<0P0Q!-I(4/QYA1G$L5%"CK]*T4[U36-X
MV'Y7O\TGCY-94P4S$7]AH8ZN.J,."6%#LU@_B]W/4$ZH;_0"$:O\+]D5[_9Z
M'1)D2HND-$:"A/'BE[Z5CC@T\(X8^*6!GW,7'\HI;ZBFD[$4.R+-VZAF&OE4
M<VN$8]Q$9:DE/F5HIR<W(LC0R9I0'I(YUTSOR1TOHFV\]OY\[&C\FK%Q@E+Y
MNE#VCR@_T#UQ^V?$=WWOG]8.,E:@?@7JYW+=(W(S\0J2_#%=*RTQE']:)+N5
M9#>7[+7-?;5/H6F"=O/1^6<+1*^"Z)T&L0#)A(E!2#"2C3QV)>/P_MDW'SZT
M>+Q?D?6M>N5J>(8M,SY'Q$>:-'+9=:9Q++; @:PBD#2%3+- G>$J"RXLE(.*
M<G *Y0Q=*&F,JB&\D<^P;^*T*[FNZPV[0W\TM& -*ZRA?=(8TS"/ZVU,MTTP
M=OL-C158.$85Q^@4]Z"SA4R%S#?U&5EJ7&%$2#(3&?H-W2?"QLC:Q6_F%L++
MBO#R%,);%@-YS)(UR"80NP9&[KP[&EQV+3R>6Z=$]Q2B%7TC=R&&D&U84&3#
MXWPMDB/_O-L?^,.A;6-Z!TG;.X5P&H82%.ZELD'N\3WRQ!M#V2+I>RZ94Z7)
M)VE*P?05>&9;@%Z=N#W_/\'.3 _7WDKL>".H76Z)9XN(+"DGMT@:,!4(&V9=
M##Q[.O\:L]HC"RE>&0^:G6K7G$UM:'6)\.R9_6NTA5 :<]WO+#VZ<5L4+WON
MR+6QU47"LV?W/)I3/! >1[$+#/I6D+H.>/;T?2\"],DB$MR61UI$>OWAN3]T
MK41U"?#L.?R+9%H#1\<D2<;+'*(:J?Y?,?#J:N#9,_92Q"Q@FO$M><#E+1F-
M&WGL*JT\=>[W[(E[(>$\0/< [J_B*(9E$\]Y3YO-D?C9]=K(_+H(^/:,_2^R
M.Z4R)&L#;)%M!:QK@&]/V"NFL6**#?'\']8_DB4$&:ZWQG-/BY)9GX)__ZTW
M<']::A&\G!7M[]P++*Q%.Z6R:+S2.(-R#,HQ%5%IG=3!(=^>W%>2AF9Q+O?)
M6C0NS1:!Z?W]DXVD+@>^/76_^Y/,WX*(\BT</?VV"#U.ES?37VQ,=1WP3ZH#
M\P3DUGCI$RI@+<3XI90W1]XN>'0U.@<W2G,[?Z#FBXK$L$$A]V*(.5T6%]ZB
MHT6:7S+70N.5-6]&0'&GF!?P^48(_=XQ]];JWPZ3OP%02P,$%     @ D8*E
M4I^@&_"Q @  X@P   T   !X;"]S='EL97,N>&ULW5=M:]LP$/XK0C]@;F)J
MXI$8MD!AL(U"\V%?E5AV!'KQ9+ES^NNGLVPG:75EW8>QS:')W3VZNT=W)YFN
M6W>2_.'(N2.]DKK=T*-SS?LD:0]'KEC[SC1<>Z0R5C'G55LG;6,Y*UMP4C)9
MWMQDB6)"TV*M.W6G7$L.IM-N0V]H4JPKH\^6E :#7\H4)X],;NB62;&W8EC+
ME)"G8%Z"X6"DL<1Y*GQ#%V!IGP*\"!JP'.,HH8T%8Q(RA._]N/P9,&FM5X64
M,\$E#89BW3#GN-5W7AD6#\87$!GEW:GQ#&O+3HOE+3T[##\^R=[8DMLYS8).
MIF(M>05TK*B/\.M,DP#HG%%>* 6KC68#A\EC%'S8 Y?R 5KXK;J*W5<D].)3
M"6T@L-5)](1&,80)"L2_C!9B7X2]_:VPI!&/QGWL_&[TH'_OC./WEE>B'_2^
MFO-CT1=X=-8T\O1!BEHK'O;^RPF+-9O\R-%8\>2SP:0<O(%;2AZY=>)P:?EA
M6;/CO9NFJ:]PSLM_D/.?K7/--;=,7I+VH_\W5_DMC)/Q]%P<T:L#.EL)7(0;
M^A7N5WGF0/:=D$[H43N*LN3ZQ3GUX1W;^PO\*KY?7_**==+M9G!#S_(77HI.
MY?.J>ZC+N.HL?X;[:)'-M[#/)73)>UYN1]76^T$D7O!9QP<<GB-WPQ-',)^
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M-_=%KLWC":[?#'!X=/X!4$L#!!0    ( )&"I5)ED'F2&0$  ,\#   3
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M  !X;"]W;W)K8F]O:RYX;6Q02P$"% ,4    " "1@J52)!Z;HJT   #X 0
M&@              @ ',$0  >&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'-0
M2P$"% ,4    " "1@J5299!YDAD!  #/ P  $P              @ &Q$@
I6T-O;G1E;G1?5'EP97-=+GAM;%!+!08     "0 ) #X"  #[$P     !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.21.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>95</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="allo-20210505.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0001001 - Document - Document and Entity Information Document</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://allogene.com/role/DocumentandEntityInformationDocument</Role>
      <ShortName>Document and Entity Information Document</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" original="allo-20210505.htm">allo-20210505.htm</File>
    <File>allo-20210331xexx991q121.htm</File>
    <File>allo-20210505.xsd</File>
    <File>allo-20210505_cal.xml</File>
    <File>allo-20210505_def.xml</File>
    <File>allo-20210505_lab.xml</File>
    <File>allo-20210505_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2019-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>16
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "allo-20210505.htm": {
   "axisCustom": 0,
   "axisStandard": 0,
   "contextCount": 1,
   "dts": {
    "calculationLink": {
     "local": [
      "allo-20210505_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "allo-20210505_def.xml"
     ]
    },
    "inline": {
     "local": [
      "allo-20210505.htm"
     ]
    },
    "labelLink": {
     "local": [
      "allo-20210505_lab.xml"
     ],
     "remote": [
      "https://xbrl.sec.gov/dei/2019/dei-doc-2019-01-31.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "allo-20210505_pre.xml"
     ]
    },
    "referenceLink": {
     "remote": [
      "https://xbrl.sec.gov/dei/2019/dei-ref-2019-01-31.xml"
     ]
    },
    "schema": {
     "local": [
      "allo-20210505.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd"
     ]
    }
   },
   "elementCount": 23,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2019-01-31": 2,
    "total": 2
   },
   "keyCustom": 0,
   "keyStandard": 95,
   "memberCustom": 0,
   "memberStandard": 0,
   "nsprefix": "allo",
   "nsuri": "http://allogene.com/20210505",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "allo-20210505.htm",
      "contextRef": "i259d1a27ddae4f849a0c7f0668bff90e_D20210505-20210505",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0001001 - Document - Document and Entity Information Document",
     "role": "http://allogene.com/role/DocumentandEntityInformationDocument",
     "shortName": "Document and Entity Information Document",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "allo-20210505.htm",
      "contextRef": "i259d1a27ddae4f849a0c7f0668bff90e_D20210505-20210505",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 0,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://allogene.com/role/DocumentandEntityInformationDocument"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://allogene.com/role/DocumentandEntityInformationDocument"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]",
        "terseLabel": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://allogene.com/role/DocumentandEntityInformationDocument"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://allogene.com/role/DocumentandEntityInformationDocument"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://allogene.com/role/DocumentandEntityInformationDocument"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://allogene.com/role/DocumentandEntityInformationDocument"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://allogene.com/role/DocumentandEntityInformationDocument"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://allogene.com/role/DocumentandEntityInformationDocument"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://allogene.com/role/DocumentandEntityInformationDocument"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://allogene.com/role/DocumentandEntityInformationDocument"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://allogene.com/role/DocumentandEntityInformationDocument"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://allogene.com/role/DocumentandEntityInformationDocument"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://allogene.com/role/DocumentandEntityInformationDocument"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://allogene.com/role/DocumentandEntityInformationDocument"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://allogene.com/role/DocumentandEntityInformationDocument"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre-commencement Issuer Tender Offer",
        "terseLabel": "Pre-commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://allogene.com/role/DocumentandEntityInformationDocument"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre-commencement Tender Offer",
        "terseLabel": "Pre-commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://allogene.com/role/DocumentandEntityInformationDocument"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://allogene.com/role/DocumentandEntityInformationDocument"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://allogene.com/role/DocumentandEntityInformationDocument"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material",
        "terseLabel": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://allogene.com/role/DocumentandEntityInformationDocument"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://allogene.com/role/DocumentandEntityInformationDocument"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications",
        "terseLabel": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://allogene.com/role/DocumentandEntityInformationDocument"
     ],
     "xbrltype": "booleanItemType"
    }
   },
   "unitCount": 0
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r2": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r3": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r4": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12"
  },
  "r5": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r6": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>17
<FILENAME>0001737287-21-000021-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001737287-21-000021-xbrl.zip
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M@%T,('U-LB[2&H:9E(L $[F&"1C<E +_N=.Y9!<!!3UAV_6,X%9^SH&(;P5
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M5M5A6KJ_YNTZ3I2FT:"J P&W6DFI$_!9>2>*8?C8C8* #A->G7W8FBF\W$+
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M828[,E9EW<(.ER5,3<\@LN%R57-*VY8JF=+Z9 NLY9(%!8]%IF 8PU+TAS1
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MX#-/I!3BU ^+A,4\Y@5D'&"4%SP)QPEC0?[WHU5,R;/Q/Q_\ U!+ P04
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MVH-AD$RX$CJ2N*^,2!<!#S.XWF]G("51H!2)8PSD21#K !?+A/LN:I4/3(P
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MNM/^!SO_!U!+ 0(4 Q0    ( )&"I5*01>,$$!L  .+'   <
M  "  0    !A;&QO+3(P,C$P,S,Q>&5X>#DY,7$Q,C$N:'1M4$L! A0#%
M  @ D8*E4JZ:UJ")%   E(<  !$              ( !2AL  &%L;&\M,C R
M,3 U,#4N:'1M4$L! A0#%     @ D8*E4HC/RU2; @  S D  !$
M     ( ! C   &%L;&\M,C R,3 U,#4N>'-D4$L! A0#%     @ D8*E4A:P
M? &. 0  &P,  !4              ( !S#(  &%L;&\M,C R,3 U,#5?8V%L
M+GAM;%!+ 0(4 Q0    ( )&"I5(RQOI9$ (  -\&   5              "
M 8TT  !A;&QO+3(P,C$P-3 U7V1E9BYX;6Q02P$"% ,4    " "1@J52=RBT
MZ( *  #37@  %0              @ '0-@  86QL;RTR,#(Q,#4P-5]L86(N
M>&UL4$L! A0#%     @ D8*E4E/P,DV]!@  NS$  !4              ( !
M@T$  &%L;&\M,C R,3 U,#5?<')E+GAM;%!+!08     !P ' -0!  !S2
"   !

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
